Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe United States | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Latin America | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Novartis Foundation | en
  • Sandoz | en
  • Egypt | en
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe United States

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latin America | es
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Sandoz | en
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Novartis in the US
        • Company at a Glance
        • By the Numbers
        • Diversity and Inclusion
        • Pay Transparency-EPIC
        • Our Code of Ethics
      • Strategy
      • Diversity and Inclusion
        • Ensuring Equity
        • The Spirit of Inclusivity
        • Toward a better society
        • Parental Leave
        • Standing for Racial Equity and Justice as One Novartis
        • Novartis US EEO / D&I Report 2021
        • Supplier Diversity
      • People and Culture
      • Products
      • Country Leadership Team
      • External Funding
      • Contact Us
      About
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Patient Assistance
      • Diseases
      • Participating in Clinical Trials
      • Patient Perspectives
      • Adverse Event Reporting
      • The STEP Program
        • Sickle Cell Disease (SCD)
        • Program Overview
        • Multiple Sclerosis (MS)
        • Cancer
        • Application for Funding to Help Address Health Disparities
        • Health Disparities
      Patients and Caregivers
    • Healthcare Professionals
      • Novartis Pipeline
      • Novartis Clinical Trials
      • Adverse Event Reporting
      Healthcare Professionals
    • ESG
      • Ethical Behavior
        • Code of Ethics
        • SpeakUp
        • PhRMA Code on Interactions with Healthcare Professionals
        • Business Principles
      • Ethics, Risk and Compliance
        • Compliance Program
        • State Laws
        • Corporate Integrity Agreement
        • Payments to HCPs & HCOs
        • Enhanced Verification Request
      • Corporate Responsibility
        • Population Health
        • Novartis in Society US Reports
        • Novartis US Foundation
        • Environmental Sustainability
        • People and Communities
      • Beacon of Hope
        • Beacon of Hope: Measurable solutions for health equity
      ESG
    • News
      • News Archive
      • Statements
      • Stories
      • Contacts
      News
    • Careers
      • Career Search
      • Meet the Teams
      • Career Programs
      • Personal Growth
      • Early Talent
      • How We Work
      • Employee Benefits
      • Diversity and Inclusion
      • Awards & Recognition
      Careers
    • Coronavirus
      Coronavirus
    Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Releases
  • Stories
  • Featured News
  • Statements
icon
News Archive Navigation Language
  • English
  • French
  • German

November 2021

  • Featured NewsNov 30, 2021
    Updated packaging now available for SANDIMMUNE® 100 mg blister packages

July 2021

  • Featured NewsJul 20, 2021
    Beacon of Hope: Addressing health disparities through holistic community-based collective action

January 2021

  • Featured NewsJan 05, 2021
    Novartis US response to COVID-19

October 2020

  • Featured NewsOct 30, 2020
    New policy related to the 340B program

September 2020

  • Featured NewsSep 30, 2020
    Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique

July 2020

  • Featured NewsJul 27, 2020
    Notice to Healthcare Providers and Entities

June 2020

  • Featured NewsJun 15, 2020
    Standing for Racial Equity and Justice as One Novartis

April 2020

  • Featured NewsApr 17, 2020
    Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative

March 2020

  • Featured NewsMar 11, 2020
    Novartis provides update on use and safety of Beovu® in patients with wet AMD

February 2020

  • Featured NewsFeb 18, 2020
    Corrective Action for Certain 100-mg SANDIMMUNE® and NEORAL® Blister Packages in the US
  • Featured NewsFeb 12, 2020
    Novartis launches new Preferred Firm Program for legal services

September 2019

  • Featured NewsSep 24, 2019
    Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement

Pagination

  • 1
  • 2
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Statements
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis US Websites
  • Oncology HCP Resources
  • Gene Therapy Network
  • Medical Information
  • Sandoz
  • Global Site
Footer Bottom
© 2022 Novartis Pharmaceuticals Corporation
  • Terms of Use
  • Privacy Policy
  • Contacts
  • About Cookies
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for US Residents Only